Abstract
Lipin 1 is a bifunctional protein that serves as a metabolic enzyme in the triglyceride synthesis pathway and regulates gene expression through direct protein-protein interactions with DNA-bound transcription factors in liver. Herein, we demonstrate that lipin 1 is a target gene of the hepatocyte nuclear factor 4α (HNF4α), which induces lipin 1 gene expression in cooperation with peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α) through a nuclear receptor response element in the first intron of the lipin 1 gene. The results of a series of gain-of-function and loss-of-function studies demonstrate that lipin 1 coactivates HNF4α to activate the expression of a variety of genes encoding enzymes involved in fatty acid catabolism. In contrast, lipin 1 reduces the ability of HNF4α to induce the expression of genes encoding apoproteins A4 and C3. Although the ability of lipin to diminish HNF4α activity on these promoters required a direct physical interaction between the two proteins, lipin 1 did not occupy the promoters of the repressed genes and enhances the intrinsic activity of HNF4α in a promoter-independent context. Thus, the induction of lipin 1 by HNF4α may serve as a mechanism to affect promoter selection to direct HNF4α to promoters of genes encoding fatty acid oxidation enzymes.
Introduction
The control of hepatic intermediary metabolism is critical to maintaining systemic energy homeostasis. For example, during conditions of nutrient scarcity (fasting), the liver takes up and oxidizes fatty acids to provide the brain and other peripheral tissues with ketone bodies and uses the chemical energy stored in fat to drive gluconeogenesis. The liver also provides lipid to other peripheral tissues by esterifying fatty acids into triglycerides (TG) and secreting them in the form of very low density lipoproteins (VLDL). Complex regulatory mechanisms have evolved to control hepatic fatty acid utilization, trafficking, and export. However, nutrient excess and obesity perturb the ability of the liver to maintain homeostasis and these hepatic metabolic abnormalities contribute to the hyperglycemia and dyslipidemia that are prevalent in type 2 diabetes mellitus.
Recent work has demonstrated that the lipin family of proteins (lipin 1, 2, and 3) are critical regulators of hepatic intermediary metabolism [1] that are strongly affected by alterations in energy homeostasis [2], [3]. Lipins are bifunctional intracellular proteins that regulate fatty acid metabolism at two distinct regulatory levels. Lipins act as phosphatidic acid phosphohydrolase (PAP) enzymes that catalyze the dephosphorylation of phosphatidic acid (PA) to generate diacylglycerol (DAG); the penultimate step in triglyceride (TG) synthesis [4], [5], [6]. Unlike other enzymes in the TG synthetic pathway that are integral membrane proteins, lipins are soluble and contain a nuclear localization signal [7], [8], [9]. Lipins also act as transcriptional regulatory proteins by associating with DNA-bound transcription factors to modulate their activity [7], [10], [11]. In liver, lipin 1 interacts with and coactivates the peroxisome proliferator-activated receptor α (PPARα) and its coactivator (PPARγ coactivator 1α (PGC-1α)) to enhance the expression of genes involved in fatty acid oxidation by recruiting in other coactivator proteins with histone acetyltransferase activity [10]. The effects of lipin 1 on hepatic fatty acid oxidation can proceed independent of PPARα, but not PGC-1α [10], suggesting that other transcription factor partners of PGC-1α are also involved in this response.
Hepatic lipin 1 expression is robustly induced in liver by food deprivation in a PGC-1α-dependent manner [10]. The induction of lipin 1 by fasting likely serves to enhance fatty acid catabolism under fasting conditions since knockdown of lipin 1 by shRNA markedly attenuates the fasting-induced increase in the expression of fatty acid oxidation enzymes. Conversely, forced lipin 1 overexpression increases the expression of these enzymes and stimulates hepatic ketone production [10]. Mice with a genetic defect in lipin 1 (fatty liver dystrophic (fld) mice) exhibit a severe hepatic steatosis characterized by marked reductions in the expression of fatty acid oxidation enzymes [10]. Thus, lipin 1 appears to be a critical regulator of hepatic fatty acid utilization.
While it is clear that lipin 1 is a direct target gene of PGC-1α, the other components of the transcriptional complex that cooperate with PGC-1α to regulate lipin 1 expression remain unclear. Herein, we demonstrate that PGC-1α works with the hepatocyte nuclear factor 4α (HNF4α) to regulate of lipin 1 expression in liver cells. We also show that the induction of lipin 1 feeds forward to modulate HNF4α activity in a promoter-specific manner to direct this nuclear receptor to activate hepatic fatty acid oxidation while suppressing expression of genes encoding apoproteins. These data further elucidate the regulatory mechanisms by which lipin 1 controls hepatic metabolism and suggest that the transcriptional regulatory function of this protein serves to fine-tune hepatic metabolic control.
Methods
Mouse Studies
All animal experiments were approved by the Animal Studies Committee of Washington University School of Medicine. C57BL/6 mice were generated from a colony established in the Washington University mouse facility. Mice constitutively deficient in lipin 1 (fld mice), were compared to wild-type (+/+) littermate control mice (Balb/cByJ strain).
Gene Expression Analyses
For quantitative PCR studies, first-strand cDNA was generated by reverse transcription using total RNA. Real-time RT-PCR was performed using the ABI PRISM 7500 sequence detection system (Applied Biosystems, Foster City, CA) and the SYBR green kit. Arbitrary units of target mRNA were corrected by measuring the levels of 36B4 RNA.
Mammalian Cell Culture and Transient Transfection
Primary cultures of mouse hepatocytes were prepared as described [12]. After a 2 h attachment period, hepatocytes were infected with adenovirus to drive overexpression of proteins defined below, then studied after 48 h of infection. Palmitate oxidation rates were determined using 3H-palmitate as previously described [2]. VLDL-TG secretion was measured using 3H-glycerol after oleate stimulation (0.3 mM) as previously described [12].
Transient Transfection and Luciferase Assays
HepG2 and HEK-293 cells were maintained in DMEM-10% fetal calf serum. Transient transfections with luciferase reporter constructs were performed by calcium-phosphate co-precipitation. SV40-driven renilla luciferase expression construct was also included in each well. For all vectors, promoterless reporters or empty vector controls were included so that equal amounts of DNA were transfected into each well. Luciferase activity was quantified 48 h after transfection by using a luminometer and the Stop & Glo® dual luciferase kit (Promega). Assays were performed in duplicate. To control for transfection efficiency, firefly luciferase activity was corrected to renilla luciferase activity.
Co-immunoprecipitation and Western Blotting Analyses
In co-immunoprecipitation (co-IP) experiments, HepG2 cells were lysed and incubations performed in NP40-containing lysis buffer (20 mM Tris HCl, 100 mM NaCl, 0.5% NP40, 0.5 mM EDTA, 0.5 mM PMSF, and protease inhibitor cocktail). Proteins were immunoprecipitated using protein A-conjugated agarose beads an antibody directed against HNF4α (Santa Cruz Biotechnology). Precipitated proteins were electrophoresed on acrylamide gels. Western blotting analyses for IP studies and to demonstrate overexpression of HA-tagged lipin 1 proteins were performed with mouse monoclonal anti-HA antibody (Covance). Mouse anti actin antibody was purchased from Sigma Chemical Co.
Chromatin Immunoprecipitation (ChIP) Assays
In experiments where ChIP was the endpoint, HepG2 cells were cultured in 10 cm dishes and infected with Ad-GFP, Ad-HNF4α, and/or Ad-lipin 1β. Approximately 48 h after infection, proteins were cross-linked to chromatin by adding formaldehyde to a final concentration of 1% and incubating for 15 minutes at room temperature. Chromatin purification and ChIP assays were performed by using a commercially available ChIP assay kit (Upstate Biotechnology) according to the manufacturer’s instructions. PCR primers were designed to flank HNF4α response elements and the sequence of these primers is available upon request. For quantification, SYBR GREEN PCR was performed using DNA obtained from ChIP.
DNA Constructs
Luciferase reporter driven by 2045 bp of the 5′ flanking region of the Lpin1 gene (−2045.Lpin1.Luc) was the gift of Karen Reue and the +2293.Lpin1.Luc, which contains 393 nucleotides of the 5′ flanking sequence, the first Lpin1 exon (51 nucleotides), and approximately 2,242 bp of the first intron of the mouse Lpin1 gene into a promoterless luciferase reporter vector (+2293-Lpin1.luc), has been recently described [13]. Ppara.Luc and Acadm.TKLuc were the gift of Bart Staels and Daniel Kelly, respectively, and have been reported and characterized previously [14], [15]. The homologous promoter-firefly luciferase reporter construct driven by the entire intergenic region between the Apoc3 and Apoa4 genes (Apoc3/Apoa4.Luc) has been described [16], [17] and was the generous gift of V. Giguerre. Apoc3/Apoa4 promoter luciferase reporter constructs containing mutations in HNF4α response elements were derived from the parent Apoc3/Apoa4.Luc construct and were provided by B. Spiegelman [16]. The Apoc3 enhancer.3X.Luc heterologous reporter construct was driven by the thymidine kinase minimal promoter and three copies of the human Apoc3 enhancer (5′-GATCTCCCAGGGCGCTGGGCAAAGGTCACCTGCTGACCAGTGGAGATGAG-3′; nuclear receptor response element is underlined). The UAS-TKLuc has also been previously described [10]. The SV40-driven renilla luciferase DNA construct was obtained from Promega.
The 924 amino acid form of mouse lipin 1 (lipin 1β) fused to an N-terminal triple HA tag was overexpressed using a pCDNA3.1 vector [10]. Expression constructs driving expression of lipin 1β protein with a site-directed mutation changing isoleucine 726 and leucine 727 to phenylalanine (LXXFF) were derived from the lipin 1β construct [4], [10]. The HNF4α (pMT-HNF4α), PGC-1α, PGC-1α-mL2 (LXXLL to LXXFF), and PGC-1β expression constructs have also been described [18], [19]. The Gal4-HNF4α expression construct has also been described [20].
Adenoviral constructs to drive expression of HA-tagged lipin-1β and/or GFP [4], [10], Ad-HNF4α [16], and mutant lipin 1β (LXXFF) [2] have been previously described. Adenoviral transductions were carried out by incubating hepatocytes with adenoviruses in a 5% FBS/DMEM media overnight in 24-well plates (0.5 ml/well) or 6-well plates (2 ml/well) at an M.O.I. of 8. Experiments were carried out 40–48 h after adenoviral transduction.
siRNA Studies
A human HNF4α-specific siRNA (siHNF4α) was obtained from Sigma. Scramble control siRNA was synthesized using a Silencer® Select siRNA kit (Ambion) as described [21]. The control siRNA and siHNF4α were transfected onto HepG2 cells using a Lipofectamine-2000 reagent (Invitrogen). At 14 hr after siRNA transfection, the cells were infected with Ad-GFP or Ad-PGC-1α and cultured for additional 34 hr and thereafter they were harvested for RNA isolation or subjected to assays measuring rates of palmitate oxidation as described above.
Statistical Analyses
Statistical comparisons were made using analysis of variance (ANOVA) coupled to Scheffe’s test. All data are presented as means ± SEM, with a statistically significant difference defined as a P value <0.05.
Results
PGC-1α Induces Lipin 1 Expression through HNF4α in HepG2 Cells
We have previously demonstrated that PGC-1α is an important regulator of lipin 1 gene expression in liver [10], but the transcription factor partners of PGC-1α that mediate this effect remain unclear. To further dissect the transcriptional mechanisms at play, we transfected HepG2 cells with expression constructs for PGC-1α or PGC-1β and Lpin1 promoter-luciferase reporter constructs. The PGC-1α responsive region was not contained in the 2 kb 5′ flanking sequence (−2045.Lpin1.Luc) that is sufficient to confer responsiveness to several other transcription factors [22], [23], [24], [25]. However, PGC-1α overexpression activated a promoter driven by 393 nucleotides of the 5′ flanking sequence, the first Lpin1 exon (53 nucleotides), and 2,240 bp of the first intron of the mouse lipin 1 gene (+2293-Lpin1.luc). This suggests that the PGC-1α-responsive element in HepG2 cells is contained in the first intron of the Lpin1 gene (Figure 1A). Interestingly, PGC-1α overexpression did not affect Lpin1 promoter activity. To begin to narrow the transcription factor partners of lipin 1 that might be mediating this response, we overexpressed PGC-1α with a site directed mutations in a leucine-rich (LXXLL to LXXFF) motif that mediates interactions with nuclear receptor partners. Mutation of the L2 domain of PGC-1α [26] was sufficient to completely block the activation of Lpin1 promoter activity (Figure 1B). These data indicate that the ability of PGC-1α to induce lipin 1 expression depended upon a transcription factor partner, likely a nuclear receptor, which interacted with the L2 domain.
Based on these results, we hypothesized that HNF4α might be involved in this response since HNF4α requires the L2 motif of PGC-1α to interact with that coactivator [27] and interacts only weakly with PGC-1β [28]. Transfection of an expression construct for HNF4α led to a 2-fold increase in Lpin1 promoter activity and this was additively enhanced by cotransfection of PGC-1α (Figure 1C). Chromatin immunoprecipitation studies confirmed that HNF4α was interacting with chromatin at two previously-identified [13] nuclear receptor response elements in the first intron of the Lpin1 gene (Figure 1D), which is consistent with the promoter mapping studies. Finally, knockdown of HNF4α protein content by using siRNA led to diminished expression of Lpin1 in HepG2 cells and abolished the induction in Lpin1 expression caused by PGC-1α overexpression (Figure 1E).
Lipin 1 Enhances the Effects of HNF4α on Fatty Acid Oxidation
We have previously demonstrated a direct protein-protein interaction between HNF4α and lipin 1 in GST pull-down assays [10]. To confirm the interaction between HNF4α and lipin 1, HNF4α was immunoprecipitated from isolated hepatocytes overexpressing lipin 1 protein that was either wild-type or harboring a mutation in the LXXIL domain of lipin 1 that mediates its interaction with PPARα [10]. Lipin 1 was found to be immuno-coprecipitated with HNF4α and the interaction required the LXXIL motif (Figure 2A). We next evaluated the functional implications of this interaction. Lipin 1 significantly enhanced HNF4α-mediated activation of the human PPARα gene promoter-luciferase reporter and multimerized HNF4α-responsive Acadm-TKLuc reporter construct (Figure 2B), suggesting that lipin 1 was acting in a feed forward manner to enhance HNF4α activity. Lipin 1 overexpression augmented the effects of HNF4α on the expression of Ppara and Acadm genes (Figure 2C) and rates of fat catabolism (Figure 2D) in hepatocytes in an LXXIL-dependent manner.
We also took a lipin 1 loss of function approach to evaluate the interaction between lipin 1 and HNF4α. Overexpression of similar amounts of HNF4α in hepatocytes from fld mice, which lack lipin 1, was less effective at inducing the expression of genes encoding PPARα and fatty acid oxidation enzymes (Cpt1a and Acadm) (Figure 3A). The increase in rates of fatty acid oxidation induced by HNF4α overexpression was blunted in fld hepatocytes compared to WT controls (Figure 3B). Basal rates of palmitate oxidation were also diminished in fld hepatocytes compared to WT controls (Figure 3B). Collectively, these data indicate that lipin 1 enhances the stimulatory effects of HNF4α on fatty acid oxidation.
Lipin 1 Suppresses the Expression of Apoproteins that are Induced by HNF4α
HNF4α is known to stimulate the expression of various genes involved in VLDL metabolism [29], whereas we have shown that lipin 1 suppresses the expression of these genes [2]. Lipin 1 overexpression suppressed the ability of HNF4α to induce the expression of Apoa4 and Apoc3 in an LXXIL motif-dependent manner (Figure 4A). HNF4α overexpression was also more potent at inducing the expression of Apoa4 and Apoc3 in fld hepatocytes compared to WT controls (Figure 4B). We also assessed rates of TG synthesis and secretion by isolated hepatocytes from WT and fld mice and found that, despite the role of lipin 1 in the TG synthesis pathway, rates of TG synthesis were not affected by lipin 1 deficiency or HNF4α overexpression (Figure 4C). Consistent with our previous work [12], rates of VLDL-TG synthesis were significantly increased in hepatocytes from fld mice infected with GFP adenovirus (Figure 4C). However, HNF4α-stimulated secretion of newly synthesized VLDL-TG, which was strongly enhanced by HNF4α overexpression, was not affected by loss of lipin 1 (Figure 4C). This may be explained by the strong stimulation of microsomal triglyceride transfer protein (Mttp) expression by HNF4α, which is not affected by lipin 1 deficiency (Figure 4B). These data suggest that lipin 1 modulates HNF4α activity to selectively induce fatty acid catabolism whilst suppressing expression of genes encoding apoproteins.
We sought to explore the molecular mechanism for the crosstalk between lipin 1 and HNF4α using the Apoc3 and Apoa4 genes as a model system. These two genes are located adjacent to one another on human chromosome 11 and are oriented in opposing directions so that the promoters and critical regulatory elements that control transcription of both genes are located in a 6 kB intergenic region [30]. HepG2 cells were transfected with a luciferase promoter construct driven by the entire intergenic region between the human Apoc3 and Apoa4 genes [17] in the presence or absence of expression constructs for HNF4α and/or lipin 1. As previously reported [16], HNF4α enhanced Apoc3/Apoa4 promoter activity compared to empty vector control (Figure 5A). Co-transfection of the lipin 1 expression vector significantly repressed basal and HNF4α-induced Apoc3/Apoa4 promoter activity (Figure 5A).
A site-directed mutation that abrogates binding of HNF4α and other nuclear receptors to a nuclear receptor response element (NRRE) proximal to the Apoc3 gene (“Apoc3 enhancer”; [16]) prevented both the lipin 1-mediated suppression and the HNF4α-induced activation of the Apoc3/Apoa4 promoter (Figure 5A). In contrast, a mutation in another predicted HNF4αRE [16] proximal to the Apoa4 gene (“Apoa4 enhancer”) did not influence the effect of either lipin 1 or HNF4α (Figure 5A). The robust HNF4α-mediated activation of a heterologous reporter containing 3 copies of the “Apoc3 enhancer” was also attenuated by cotransfection of lipin 1β expression vector in HEK-293 cells (Figure 5B).
Lipin 1 is not Associated with Chromatin in the Apoc3 Promoter
We sought to further dissect the transcriptional regulatory mechanisms mediating the divergent effects of lipin 1 on HNF4α activity. Consistent with the gene expression and promoter assays above, chromatin immunoprecipitation (ChIP) analyses demonstrated that HNF4α occupancy of the Apoc3 promoter was diminished by lipin 1 overexpression, whereas HNF4α occupancy of the Ppara promoter was significantly increased by lipin 1 (Figure 6A). However, ChIP analyses utilizing an antibody to the HA epitope tag of lipin 1 did not detect a significant interaction between lipin 1 and chromatin in the Apoc3 promoter (Figure 6A). In contrast, significant cross-linking of lipin 1 to the Ppara promoter was detected. To examine the effects of lipin 1 on HNF4α intrinsic activity in a promoter-independent fashion, the activity of a Gal4-HNF4α fusion construct on a multimerized Gal4-response element-driven luciferase reporter (UAS-TKLuc) was examined. Lipin 1 overexpression enhanced Gal4-HNF4α activity by more than 3-fold in this mammalian two-hybrid system (Figure 6B). We propose that the suppression of Apoc3/Apoa4 promoter activity is not mediated via an active repression mechanism and that lipin 1 may influence HNF4α promoter occupancy by directing it towards promoters of genes encoding proteins that affect fatty acid oxidation.
Discussion
HNF4α is a nuclear receptor transcription factor that is a critical regulator of hepatic gene expression. Previous work has demonstrated important roles for HNF4α in regulating the expression of enzymes involved in VLDL metabolism [16], [31], [32], [33], fatty acid oxidation [18], and a broad profile of genes that define liver development [34]. In this work, we show that the expression of Lpin1 is also under the control of HNF4α in HepG2 cells and hepatocytes and that this occurs via a direct transcriptional mechanism involving a promoter in the first intron of the Lpin1 gene. There have been hints in previous studies using ‘omic’ approaches that lipin 1 may be a target gene of HNF4α. Lpin1 was down-regulated by siRNA against HNF4α and identified in HNF4α ChIP-seq experiments by Bolotin and collegues [35]. In that work, the interaction of HNF4α was generally localized to 3′ to the transcriptional start site of the Lpin1 gene, which coincides with our findings using promoter luciferase reporter constructs and targeted ChIP approaches. We have also shown that PGC-1α is a critical regulator of lipin 1 expression [10]. HNF4α is also an important partner of PGC-1α for mediating many aspects of the hepatic fasting response; a physiologic condition associated with increased lipin 1 expression [10]. In cardiac myocytes, we have recently shown that PGC-1α coactivates member of the ERR family through these same response elements to induce lipin 1 expression [13]. This suggests that the nuclear receptor partner coactivated by PGC-1α varies depending upon the cell type and expression level of the partners. HNF4α is enriched in hepatocytes, but few other tissues [31]. ERRα and ERRγ expression levels were at or below the edge of detection in HepG2 cells (unpublished observation), but these nuclear receptors are well expressed in muscle cells [27], [36]. Collectively, these data strongly support the idea that lipin 1 is a direct HNF4α target gene in liver cells that is induced in physiologic conditions wherein PGC-1α is activated to coactivate HNF4α.
We have previously shown that lipin 1 and HNF4α physically interact [10], but the physiologic consequences of the interaction and the induction of lipin 1 by HNF4α was not clear. In this work, we showed that increased lipin 1 availability affected HNF4α activity in a pathway-specific manner, suggesting that the activation of lipin 1 serves to feed forward and modulate HNF4α activity. Lipin 1 enhanced HNF4α-mediated activation of fatty acid oxidation while abrogating the ability of HNF4α to induce Apoa4 and Apoc3 gene expression. In the nucleus, lipin 1 can function as either a coactivator or corepressor depending upon the context of its transcription factor partner. Lipin 1 is most likely a molecular scaffold that recruits histone acetyltransferases or deacetylases to enhance or repress transcription depending upon the transcription factor partner [10], [11]. However, since ChIP analyses did not detect the presence of lipin 1 on the Apoc3 enhancer and Gal4-HNF4α activity, a measure of intrinsic activity independent of promoter binding, was enhanced by lipin 1, lipin 1 is probably not inhibiting HNF4α activity by an active repression mechanism. Rather, we surmise that lipin 1 may be mediating this effect by binding to HNF4α and directing its binding to the promoter of one gene versus another. Other coregulatory proteins that act in a promoter-specific manner have been reported. For example, in adipocytes, PGC-1α strongly coactivates PPARγ on the Ucp1 promoter, but does not enhance expression of Fabp4 [37], which is also a robust and primary PPARγ target gene [38]. Although it is still unclear how promoter selectivity by coregulatory proteins is mediated, it is possible that the presence of other response elements and DNA-bound transcription factors on certain promoters is required to influence occupancy.
In many ways, the present studies clarify several mechanistic questions from our previous work. For example, although PPARα is coactivated by lipin 1, PPARα deficiency did not affect the transcriptional effects of lipin 1 in liver [10]. The present data indicate that this observation can be explained by the HNF4α-lipin 1 interaction. We also previously reported that Apoa4 is markedly overexpressed in liver of fld mice [39], lipin 1 overexpression suppressed the expression of Apoc3 and Apoa4, and the transcriptional activity of lipin 1 was required for this repressive effect [2]. In this work, we provide a more detailed mechanistic explanation for this observation using the Apoc3/Apoa4 gene cluster, which is well-characterized as an HNF4α target [16], [31], [40], [41], [42], [43]. However, it is unlikely that the modulation of Apoc3/Apoa4 expression per se is sufficient to explain our previous report that lipin 1inhibits hepatic VLDL-TG secretion [44], [45], [46]. HNF4α overexpression was equally efficacious at increasing VLDL-TG secretion in WT and fld hepatocytes, likely because of a strong induction of Mttp, which is known to be sufficient to stimulate VLDL secretion. The identification of the gene targets mediating this response will be the subject of future inquiry.
In conclusion, we demonstrate herein that the gene encoding lipin 1 is direct target gene of HNF4α that feeds forward to modulate HNF4α activity, seemingly in a promoter-specific manner. Whereas lipin 1 promotes the expression of genes encoding fatty acid oxidation enzymes in response to HNF4α overexpression, lipin overexpression impedes the induction of apolipoprotein gene expression by this nuclear receptor. These data suggest that lipin 1 functions to promote the catabolic actions of HNF4α, which fits with the induction of lipin 1 in liver of starved mice when rates of fatty acid oxidation are high. These findings also suggest that promoting expression of lipin 1 in liver could help to clear liver fat by promoting its degradation in β-oxidative pathways.
Acknowledgments
We thank Drs. Daniel Kelly, Bruce Spiegelman, Vincent Giguere, Natasha Kralli, Iannis Talianidis, and Jongsook Kim Kemper for generous gifts of DNA and adenoviral constructs utilized in these studies.
Funding Statement
This work was also supported by the National Institutes of Health grant R01 DK78187 (to BNF) and was also supported, in part, by the Digestive Diseases Research Core Center (P30 DK52574) and the Nutrition Obesity Research Center (NORC) (P30 DK56341) of Washington University School of Medicine. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
References
- 1.Reue K, Zhang P (2007) The lipin protein family: Dual roles in lipid biosynthesis and gene expression. FEBS Lett. [DOI] [PMC free article] [PubMed]
- 2. Chen Z, Gropler MC, Norris J, Lawrence JC Jr, Harris TE, et al. (2008) Alterations in hepatic metabolism in fld mice reveal a role for lipin 1 in regulating VLDL-triacylglyceride secretion. Arterioscler Thromb Vasc Biol 28: 1738–1744. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Croce MA, Eagon JC, LaRiviere LL, Korenblat KM, Klein S, et al. (2007) Hepatic lipin 1beta expression is diminished in insulin-resistant obese subjects and is reactivated by marked weight loss. Diabetes 56: 2395–2399. [DOI] [PubMed] [Google Scholar]
- 4. Harris TE, Huffman TA, Chi A, Shabanowitz J, Hunt DF, et al. (2007) Insulin controls subcellular localization and multisite phosphorylation of the phosphatidic acid phosphatase, lipin 1. J Biol Chem 282: 277–286. [DOI] [PubMed] [Google Scholar]
- 5. Han GS, Wu WI, Carman GM (2006) The Saccharomyces cerevisiae Lipin homolog is a Mg2+-dependent phosphatidate phosphatase enzyme. J Biol Chem 281: 9210–9218. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Donkor J, Sariahmetoglu M, Dewald J, Brindley DN, Reue K (2007) Three mammalian lipins act as phosphatidate phosphatases with distinct tissue expression patterns. J Biol Chem 282: 3450–3457. [DOI] [PubMed] [Google Scholar]
- 7. Santos-Rosa H, Leung J, Grimsey N, Peak-Chew S, Siniossoglou S (2005) The yeast lipin Smp2 couples phospholipid biosynthesis to nuclear membrane growth. Embo J 24: 1931–1941. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Péterfy M, Phan J, Xu P, Reue K (2001) Lipodystrophy in the fld mouse results from mutation of a new gene encoding a nuclear protein, lipin. Nat Genet 27: 121–124. [DOI] [PubMed] [Google Scholar]
- 9. Peterfy M, Phan J, Reue K (2005) Alternatively spliced lipin isoforms exhibit distinct expression pattern, subcellular localization, and role in adipogenesis. J Biol Chem 280: 32883–32889. [DOI] [PubMed] [Google Scholar]
- 10. Finck BN, Gropler MC, Chen Z, Leone TC, Croce MA, et al. (2006) Lipin 1 is an inducible amplifier of the hepatic PGC-1alpha/PPARalpha regulatory pathway. Cell Metab 4: 199–210. [DOI] [PubMed] [Google Scholar]
- 11. Kim HB, Kumar A, Wang L, Liu GH, Keller SR, et al. (2010) Lipin 1 represses NFATc4 transcriptional activity in adipocytes to inhibit secretion of inflammatory factors. Mol Cell Biol 30: 3126–3139. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Chen Z, Fitzgerald RL, Averna MR, Schonfeld G (2000) A targeted apolipoprotein B-38.9-producing mutation causes fatty livers in mice due to the reduced ability of apolipoprotein B-38.9 to transport triglycerides. J Biol Chem 275: 32807–32815. [DOI] [PubMed] [Google Scholar]
- 13. Mitra MS, Schilling JD, Wang X, Jay PY, Huss JM, et al. (2011) Cardiac lipin 1 expression is regulated by the peroxisome proliferator activated receptor γ coactivator 1α/estrogen related receptor axis J Mol Cell Cardiol. 51: 120–128. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14. Leone TC, Cresci S, Carter ME, Zhang Z, Lala DS, et al. (1995) The human medium chain acyl-CoA dehydrogenase gene promoter consists of a complex arrangement of nuclear receptor response elements and Sp1 binding sites. J Biol Chem 270: 24622. [PubMed] [Google Scholar]
- 15. Pineda Torra I, Jamshidi Y, Flavell DM, Fruchart J-C, Staels B (2002) Characterization of the Human PPAR{alpha} Promoter: Identification of a Functional Nuclear Receptor Response Element. Mol Endocrinol 16: 1013–1028. [DOI] [PubMed] [Google Scholar]
- 16. Rhee J, Ge H, Yang W, Fan M, Handschin C, et al. (2006) Partnership of PGC-1alpha and HNF4alpha in the regulation of lipoprotein metabolism. J Biol Chem 281: 14683–14690. [DOI] [PubMed] [Google Scholar]
- 17. Carrier JC, Deblois G, Champigny C, Levy E, Giguere V (2004) Estrogen-related receptor alpha (ERRalpha) is a transcriptional regulator of apolipoprotein A-IV and controls lipid handling in the intestine. J Biol Chem 279: 52052–52058. [DOI] [PubMed] [Google Scholar]
- 18. Carter ME, Gulick T, Raisher BD, Caira T, Ladias JA, et al. (1993) Hepatocyte nuclear factor-4 activates medium chain acyl-CoA dehydrogenase gene transcription by interacting with a complex regulatory element. J Biol Chem 268: 13805–13810. [PubMed] [Google Scholar]
- 19. Kressler D, Schreiber SN, Knutti D, Kralli A (2002) The PGC-1-related protein PERC is a selective coactivator of estrogen receptor alpha. J Biol Chem 277: 13918–13925. [DOI] [PubMed] [Google Scholar]
- 20. Ponugoti B, Fang S, Kemper JK (2007) Functional interaction of hepatic nuclear factor-4 and peroxisome proliferator-activated receptor-gamma coactivator 1alpha in CYP7A1 regulation is inhibited by a key lipogenic activator, sterol regulatory element-binding protein-1c. Mol Endocrinol 21: 2698–2712. [DOI] [PubMed] [Google Scholar]
- 21. Gropler MC, Harris TE, Hall AM, Wolins NE, Gross RW, et al. (2009) Lipin 2 is a liver-enriched phosphatidate phosphohydrolase enzyme that is dynamically regulated by fasting and obesity in mice. J Biol Chem 284: 6763–6772. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Zhang P, O’Loughlin L, Brindley DN, Reue K (2008) Regulation of lipin-1 gene expression by glucocorticoids during adipogenesis. J Lipid Res. [DOI] [PMC free article] [PubMed]
- 23. Pearen MA, Myers SA, Raichur S, Ryall JG, Lynch GS, et al. (2008) The orphan nuclear receptor, NOR-1, a target of beta-adrenergic signaling, regulates gene expression that controls oxidative metabolism in skeletal muscle. Endocrinology 149: 2853–2865. [DOI] [PubMed] [Google Scholar]
- 24. Koh YK, Lee MY, Kim JW, Kim M, Moon JS, et al. (2008) Lipin1 is a key factor for the maturation and maintenance of adipocytes in the regulatory network with CCAAT/enhancer-binding protein alpha and peroxisome proliferator-activated receptor gamma 2. J Biol Chem 283: 34896–34906. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25. Ryu D, Oh KJ, Jo HY, Hedrick S, Kim YN, et al. (2009) TORC2 regulates hepatic insulin signaling via a mammalian phosphatidic acid phosphatase, LIPIN1. Cell Metab 9: 240–251. [DOI] [PubMed] [Google Scholar]
- 26. Huss JM, Torra IP, Staels B, Giguere V, Kelly DP (2004) Estrogen-related receptor alpha directs peroxisome proliferator-activated receptor alpha signaling in the transcriptional control of energy metabolism in cardiac and skeletal muscle. Mol Cell Biol 24: 9079–9091. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27. Huss JM, Kopp RP, Kelly DP (2002) Peroxisome proliferator-activated receptor coactivator-1alpha (PGC-1alpha) coactivates the cardiac-enriched nuclear receptors estrogen-related receptor-alpha and -gamma. Identification of novel leucine-rich interaction motif within PGC-1alpha. J Biol Chem 277: 40265–40274. [DOI] [PubMed] [Google Scholar]
- 28. Lin J, Tarr PT, Yang R, Rhee J, Puigserver P, et al. (2003) PGC-1beta in the regulation of hepatic glucose and energy metabolism. J Biol Chem 278: 30843–30848. [DOI] [PubMed] [Google Scholar]
- 29. Yin L, Ma H, Ge X, Edwards PA, Zhang Y (2011) Hepatic hepatocyte nuclear factor 4alpha is essential for maintaining triglyceride and cholesterol homeostasis. Arterioscler Thromb Vasc Biol 31: 328–336. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30. Lai CQ, Parnell LD, Ordovas JM (2005) The APOA1/C3/A4/A5 gene cluster, lipid metabolism and cardiovascular disease risk. Curr Opin Lipidol 16: 153–166. [DOI] [PubMed] [Google Scholar]
- 31. Sladek FM, Zhong WM, Lai E, Darnell JE Jr (1990) Liver-enriched transcription factor HNF-4 is a novel member of the steroid hormone receptor superfamily. Genes Dev 4: 2353–2365. [DOI] [PubMed] [Google Scholar]
- 32. Sheena V, Hertz R, Nousbeck J, Berman I, Magenheim J, et al. (2005) Transcriptional regulation of human microsomal triglyceride transfer protein by hepatocyte nuclear factor-4alpha. J Lipid Res 46: 328–341. [DOI] [PubMed] [Google Scholar]
- 33. Hayhurst GP, Lee YH, Lambert G, Ward JM, Gonzalez FJ (2001) Hepatocyte nuclear factor 4alpha (nuclear receptor 2A1) is essential for maintenance of hepatic gene expression and lipid homeostasis. Mol Cell Biol 21: 1393–1403. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34. Battle MA, Konopka G, Parviz F, Gaggl AL, Yang C, et al. (2006) Hepatocyte nuclear factor 4alpha orchestrates expression of cell adhesion proteins during the epithelial transformation of the developing liver. Proc Natl Acad Sci U S A 103: 8419–8424. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35. Bolotin E, Liao H, Ta TC, Yang C, Hwang-Verslues W, et al. (2010) Integrated approach for the identification of human hepatocyte nuclear factor 4alpha target genes using protein binding microarrays. Hepatology 51: 642–653. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36. Huss JM, Kelly DP (2004) Nuclear receptor signaling and cardiac energetics. Circ Res 95: 568–578. [DOI] [PubMed] [Google Scholar]
- 37. Puigserver P, Wu Z, Park CW, Graves R, Wright M, et al. (1998) A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 92: 829–839. [DOI] [PubMed] [Google Scholar]
- 38. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM (1994) mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 8: 1224–1234. [DOI] [PubMed] [Google Scholar]
- 39. Langner CA, Birkenmeier EH, Ben-Zeev O, Schotz MC, Sweet HO, et al. (1989) The fatty liver dystrophy (fld) mutation. A new mutant mouse with a developmental abnormality in triglyceride metabolism and associated tissue-specific defects in lipoprotein lipase and hepatic lipase activities. J Biol Chem 264: 7994–8003. [PubMed] [Google Scholar]
- 40. Ladias JA, Hadzopoulou-Cladaras M, Kardassis D, Cardot P, Cheng J, et al. (1992) Transcriptional regulation of human apolipoprotein genes ApoB, ApoCIII, and ApoAII by members of the steroid hormone receptor superfamily HNF-4, ARP-1, EAR-2, and EAR-3. J Biol Chem 267: 15849–15860. [PubMed] [Google Scholar]
- 41. Ktistaki E, Lacorte JM, Katrakili N, Zannis VI, Talianidis I (1994) Transcriptional regulation of the apolipoprotein A-IV gene involves synergism between a proximal orphan receptor response element and a distant enhancer located in the upstream promoter region of the apolipoprotein C-III gene. Nucleic Acids Res 22: 4689–4696. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42. Hanniman EA, Lambert G, Inoue Y, Gonzalez FJ, Sinal CJ (2006) Apolipoprotein A-IV is regulated by nutritional and metabolic stress: involvement of glucocorticoids, HNF-4 alpha, and PGC-1 alpha. J Lipid Res 47: 2503–2514. [DOI] [PubMed] [Google Scholar]
- 43. Zannis VI, Kan HY, Kritis A, Zanni E, Kardassis D (2001) Transcriptional regulation of the human apolipoprotein genes. Front Biosci 6: D456–504. [DOI] [PubMed] [Google Scholar]
- 44. Ebara T, Ramakrishnan R, Steiner G, Shachter NS (1997) Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E. J Clin Invest 99: 2672–2681. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45. Hirano T, Takahashi T, Saito S, Tajima H, Ebara T, et al. (2001) Apoprotein C-III deficiency markedly stimulates triglyceride secretion in vivo: comparison with apoprotein E. Am J Physiol Endocrinol Metab. 281: E665–669. [DOI] [PubMed] [Google Scholar]
- 46. Duverger N, Tremp G, Caillaud JM, Emmanuel F, Castro G, et al. (1996) Protection against atherogenesis in mice mediated by human apolipoprotein A-IV. Science 273: 966–968. [DOI] [PubMed] [Google Scholar]